Subcutaneous daratumumab: Phase Ib started

Halozyme began an open-label, international Phase Ib trial to evaluate subcutaneous daratumumab in 28-day cycles in about 128 patients. A dose-escalation part will evaluate 1,200 and 1,800 mg subcutaneous daratumumab weekly for cycles 1-2, every 2 weeks in cycles 3-6 and every 4 weeks thereafter. Following a safety review, a third cohort may be enrolled to test a higher dose. The second part of the trial will compare the dose selected from the first part vs. 1,200 mg IV daratumumab in the same dosing schedule. ...